{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:53:27Z","timestamp":1785855207258,"version":"3.56.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1017\/s0265021505000475","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T05:12:29Z","timestamp":1115183549000},"page":"283-288","source":"Crossref","is-referenced-by-count":9,"title":["Phosphodiesterase-III-inhibition with amrinone leads to contracture development in skeletal muscle preparations of malignant hyperthermia susceptible swine"],"prefix":"10.1097","volume":"22","author":[{"given":"M.","family":"Fiege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Wappler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Weisshorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. U.","family":"Gerbershagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kolodzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schulte Esch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210207","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/00003643-200110000-00002","article-title":"Malignant hyperthermia.","volume":"18","author":"Wappler","year":"2001","journal-title":"Eur J Anaesthesiol"},{"key":"R3-7-20210207","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1152\/physrev.1996.76.2.537","article-title":"Malignant hyperthermia: excitation-contraction coupling, Ca2 release channel, and cell Ca2 regulation defects.","volume":"76","author":"Mickelson","year":"1996","journal-title":"Physiol Rev"},{"key":"R4-7-20210207","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/bja\/87.5.794","article-title":"Pathophysiological role of the serotonin system in malignant hyperthermia.","volume":"87","author":"Wappler","year":"2001","journal-title":"Br J Anaesth"},{"key":"R5-7-20210207","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/0140-6736(91)93052-B","article-title":"Inositol-1,4,5-trisphosphate and malignant hyperthermia.","volume":"337","author":"Scholz","year":"1991","journal-title":"Lancet"},{"key":"R6-7-20210207","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1172\/JCI110355","article-title":"High skeletal muscle adenylate cyclase in malignant hyperthermia.","volume":"68","author":"Willner","year":"1981","journal-title":"J Clin Invest"},{"key":"R7-7-20210207","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1042\/bst0120357","article-title":"A biochemical abnormality found in muscle from unstressed malignant-hyperpyrexia-susceptible humans.","volume":"12","author":"Ellis","year":"1984","journal-title":"Biochem Soc Trans"},{"key":"R8-7-20210207","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1399-6576.1993.tb03768.x","article-title":"Biochemical changes in malignant hyperthermia susceptible swine: cyclic AMP, inositol phosphates, 1, 1- and 2-adrenoceptors in skeletal and cardiac muscle.","volume":"37","author":"Scholz","year":"1993","journal-title":"Acta Anaesthesiol Scand"},{"key":"R9-7-20210207","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJM198601303140506","article-title":"New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1.","volume":"314","author":"Colucci","year":"1986","journal-title":"New Engl J Med"},{"key":"R10-7-20210207","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00005344-198914003-00003","article-title":"Phosphodiesterase inhibition and positive inotropic effects.","volume":"14","author":"Schmitz","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"R11-7-20210207","first-page":"65","article-title":"Cyclic AMP and phosphodiesterase inhibition in skeletal muscle: a potent trigger or a cofactor for malignant hyperthermia?","volume":"60","author":"Hartung","year":"1994","journal-title":"Minerva Anestesiologica"},{"key":"R12-7-20210207","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1055\/s-2007-994811","article-title":"Diagnostik der Disposition zur Malignen Hyperthermie durch einen in vitro Kontrakturtest mit dem Phosphodiesterase-III-Hemmstoff Enoximon.","volume":"33","author":"Fiege","year":"1998","journal-title":"Anasthesiol Intensivmed Notfallmed Schmerzther"},{"key":"R13-7-20210207","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0952-8180(00)00124-0","article-title":"Effects of the phosphodiesterase-III inhibitor enoximone on skeletal muscle specimens from malignant hyperthermia susceptible patients.","volume":"12","author":"Fiege","year":"2000","journal-title":"J Clin Anesth"},{"key":"R14-7-20210207","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/346569a0","article-title":"Intramembrane charge movement restored in dysgenic skeletal muscle by injection of dihydropyridine receptor cDNAs.","volume":"346","author":"Adams","year":"1990","journal-title":"Nature"},{"key":"R15-7-20210207","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1126\/science.1862346","article-title":"Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia.","volume":"253","author":"Fujii","year":"1991","journal-title":"Science"},{"key":"R16-7-20210207","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1399-6576.1997.tb04820.x","article-title":"In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects.","volume":"41","author":"Ording","year":"1997","journal-title":"Acta Anaesthesiol Scand"},{"key":"R17-7-20210207","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D","article-title":"Genetics and pathogenesis of malignant hyperthermia.","volume":"23","author":"Jurkat-Rott","year":"2000","journal-title":"Muscle Nerve"},{"key":"R18-7-20210207","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/bja\/86.2.283","article-title":"Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia.","volume":"86","author":"Urwyler","year":"2001","journal-title":"Br J Anaesth"},{"key":"R19-7-20210207","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0165-6147(91)90484-A","article-title":"Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.","volume":"12","author":"Nicholson","year":"1991","journal-title":"Trend Pharmacol Sci"},{"key":"R20-7-20210207","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0163-7258(91)90039-O","article-title":"Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function.","volume":"51","author":"Thompson","year":"1991","journal-title":"Pharmacol Ther"},{"key":"R21-7-20210207","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2165\/00003495-199345050-00003","article-title":"Inotropic support of the critically ill patient. A review of the agents.","volume":"45","author":"Kulka","year":"1993","journal-title":"Drugs"},{"key":"R22-7-20210207","first-page":"65","article-title":"Phosphodiesterase inhibition and positive inotropy in failing human myocardium.","volume":"87","author":"Schmitz","year":"1992","journal-title":"Basic Res Cardiol"},{"key":"R23-7-20210207","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00003643-200006000-00005","article-title":"Inositol 1,4,5-trisphosphate synthesis in mononuclear white blood cells of malignant hyperthermia-susceptible and normal human beings, following in vitro exposure to halothane, caffeine and ryanodine.","volume":"17","author":"Martens","year":"2000","journal-title":"Eur J Anaesthesiol"},{"key":"R24-7-20210207","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/bja\/56.11.1243","article-title":"Cyclic AMP in normal and malignant hyperpyrexia susceptible individuals following exercise.","volume":"56","author":"Stanec","year":"1984","journal-title":"Br J Anaesth"},{"key":"R25-7-20210207","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00000542-200102000-00029","article-title":"Rhabdomyolysis following cardiopulmonary bypass and treatment with enoximone in a patient susceptible to malignant hyperthermia.","volume":"94","author":"Riess","year":"2001","journal-title":"Anesthesiology"},{"key":"R26-7-20210207","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/00000542-200304000-00022","article-title":"In vitro and in vivo effects of the phosphodiesterase-III-inhibitor enoximone on malignant hyperthermia susceptible swine.","volume":"98","author":"Fiege","year":"2003","journal-title":"Anesthesiology"}],"container-title":["European Journal of Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1017\/S0265021505000475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:31:10Z","timestamp":1785853870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003643-200504000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1017\/s0265021505000475","relation":{},"ISSN":["0265-0215"],"issn-type":[{"value":"0265-0215","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}